Evidence map›Paper›PMID 37568809›Full record

ArticleCancers2023

Efficient Convolution Network to Assist Breast Cancer Diagnosis and Target Therapy.

Ching-Wei Wang, Kai-Lin Chu, Hikam Muzakky, Yi-Jia Lin, Tai-Kuang Chao

Abstract read
In one paragraph

Article in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Ching-Wei WangGraduate Institute of Biomedical Engineering, National Taiwan University of Science and Technology, Taipei 106335, Taiwan.ORCID 0000-0001-9992-6863
Kai-Lin ChuGraduate Institute of Biomedical Engineering, National Taiwan University of Science and Technology, Taipei 106335, Taiwan.
Hikam MuzakkyGraduate Institute of Biomedical Engineering, National Taiwan University of Science and Technology, Taipei 106335, Taiwan.
Yi-Jia LinDepartment of Pathology, Tri-Service General Hospital, Taipei 11490, Taiwan.ORCID 0000-0002-8073-8659
Tai-Kuang ChaoDepartment of Pathology, Tri-Service General Hospital, Taipei 11490, Taiwan.ORCID 0000-0001-8219-6382

Funding

National Taiwan University of Science and Technology - Tri-Service General Hospital NTUST-TSGH-112-02the national science and technology council, Taiwan 112-2221-E-011-052Tri-Service General Hospital, Taipei, Taiwan TSGH-A-111010Tri-Service General Hospital, Taipei, Taiwan TSGH-A-112008Tri-Service General Hospital, Taipei, Taiwan TSGH-D-109094Tri-Service General Hospital, Taipei, Taiwan TSGH-D-110036
6 · The paper itself

Abstract

Breast cancer is the leading cause of cancer-related deaths among women worldwide, and early detection and treatment has been shown to significantly reduce fatality rates from severe illness. Moreover, determination of the human epidermal growth factor receptor-2 (HER2) gene amplification by Fluorescence in situ hybridization (FISH) and Dual in situ hybridization (DISH) is critical for the selection of appropriate breast cancer patients for HER2-targeted therapy. However, visual examination of microscopy is time-consuming, subjective and poorly reproducible due to high inter-observer variability among pathologists and cytopathologists. The lack of consistency in identifying carcinoma-like nuclei has led to divergences in the calculation of sensitivity and specificity. This manuscript introduces a highly efficient deep learning method with low computing cost. The experimental results demonstrate that the proposed framework achieves high precision and recall on three essential clinical applications, including breast cancer diagnosis and human epidermal receptor factor 2 (HER2) amplification detection on FISH and DISH slides for HER2 target therapy. Furthermore, the proposed method outperforms the majority of the benchmark methods in terms of IoU by a significant margin (p<0.001) on three essential clinical applications. Importantly, run time analysis shows that the proposed method obtains excellent segmentation results with notably reduced time for Artificial intelligence (AI) training (16.93%), AI inference (17.25%) and memory usage (18.52%), making the proposed framework feasible for practical clinical usage.

Indexed as

breast cancer metastasesbreast cancer target therapydilated soft label deep learninghistopathology

Identifiers

PMID37568809
PMCPMC10416960

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.